Adult

When women receive less pay than men for the same work, they were about two and a half times more likely to "have major depressive disorder," and about four times more likely to "have generalized anxiety disorder" than their male counterparts.  But when women were earning more than men, the odds were 1.2 and 1.5 respectively. The use of psychiatric terminology ("major depressive disorder" and "generalized anxiety disorder") constitutes something of a barrier to communication here, but the general message is clear: people (in this case women) who are routinely treated unfairly and discriminately are more likely to be depressed and anxious, than those not so treated.

The Scientific American reports on an in-depth reanalysis revealing widespread underreporting of negative side effects, including suicide attempts and aggressive behavior. Article →

“In a small but growing number of cases across the nation, lawyers are blaming the U.S. military's heavy use of psychotropic drugs for their...

Following an extensive systematic review of treatments for major depression, the American College of Physicians (ACP) issued a recommendation to clinicians suggesting cognitive behavioral therapy (CBT) as a first-line treatment for major depressive disorder along with second-generation antidepressants. The results of the review revealed that CBT and antidepressants have similar levels of effectiveness but that antidepressants present serious side-effects and higher relapse rates.

After undergoing a nine-week cognitive behavioral therapy (CBT) treatment for social anxiety, patients show changes to both the physical structure of their brain and its activity, according to a new study published in Translational Psychiatry. The amygdala is most closely associated with the experience of fear and this study found that patients receiving CBT with reduced social anxiety had significant changes to this section of the brain.

"Eleanor Longden started hearing voices when she was 18. She was drugged and hospitalised, then told she was schizophrenic. A psychiatrist even told her...

A study published in this month’s issue of the Journal of Clinical Psychiatry found that the use of antidepressant drugs was associated with an...

MIA contributor Jonathan Leo, writing for Slate, weighs in on the research that claims to have discovered a genetic basis for schizophrenia. “We now...

“Findings from the British Psychological Society and New Savoy staff wellbeing survey in 2015 show that 46% of psychological professionals surveyed report depression. 49.5%...

Last week, the headlines blared: "Schizophrenia breakthrough as genetic study reveals link to brain changes!"  We heard that our best hope for treating “schizophrenia” is to understand it at a genetic level, and that this new breakthrough would get us really started on that mission, as it showed how a genetic variation could lead to the more intense pruning of brain connections, which is often seen in those diagnosed with schizophrenia.  “For the first time, the origin of schizophrenia is no longer a complete black box,” said one (while admitting that "it's still early days").  The acting director of the National Institute of Mental Health (NIMH) described the study as “a crucial turning point in the fight against mental illness.” But is all this hype justified?

In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...

Dutch psychiatrist and epidemiologist, Jim van Os, has renewed his call to drop schizophrenia as a disease classification. “Several recent papers by different authors...

I urge parents, doctors, educators and everyone concerned with the well-being of children to take a look at the debate on ADHD presented in the Times. The series of articles makes it clear that the hard line separating ADHD-like behavior from normal childhood reactions to environmental stress or normal developmental phases is beginning to soften. The number of ADHD diagnoses in the United Sates has exploded by 300 percent since 1983.

Last week, after the US Preventative Services Task Force (USPSTF) made a recommendation for increased mental health and depression screening “stories in the New York Times,...

Pioneering research by mood disorder experts at Newcastle University has questioned the effectiveness of metyrapone, a drug suggested to treat depression. "Our research has...

A woman in Texas attempted suicide while in the active group of a clinical trial for smoking-cassation drugs Chantix and Zyban, both known to...

The largest-ever meta-analysis of antidepressant trials appeared yesterday in the British Medical Journal. Researchers from the Cochrane Collaboration reviewed 70 trials (involving 18,526 subjects), to find that - counter to the initially-reported findings - antidepressants doubled the risk of suicide and aggression in subjects under 18. This risk had been misrepresented in the original study reports, the authors say, and suggest that the risks to adults may be similarly under-reported.

Four weeks ago, after I wrote a blog about a study that concluded there was no good evidence that antipsychotics improved long-term outcomes for people diagnosed with schizophrenia, I was cc’d on an email that had been sent to a number of “thought leaders” about what I had written. At least as I read the email, it put me into the usual pigeonhole for critics of psychiatric drugs: I apparently was globally “against” medications, and I had displayed a type of simplistic “categorical” thinking. All of this led to my having an email exchange with Allen Frances, and his laying out, in his opinion, the considerable "collateral damage" my writings had done.

“Overall, this study showed that the information and awareness campaign had almost no significant effects on the general public's attitudes toward people affected by either schizophrenia or depression,” the researchers, led by German medical sociologist Anna Makowski, wrote. “One could assume that deeply rooted convictions cannot be modified by rather time-limited and general activities targeted at the public.”

Mad In America contributor and prescription drug addiction reformer Barry Haslam has “taken his fight to the world stage by helping create an international...

Writing for Huffpost, medical doctor Lawrence Diller looks at the effects of the ever increasing diagnoses for ADHD and the addiction and abuse issues...

A study published in this month’s issue of Stroke found that antidepressants may increase the risk of microbleeds in the brain. Both SSRI and SNRI antidepressants can disrupt natural clotting mechanisms and lead to increased adverse bleeding incidents and prolonged bleeding times.

In his NY Times article “A Drug to Cure Fear,” Richard Friedman noted: “It has been an article of faith in neuroscience and psychiatry that, once formed, emotional memories are permanent.” This has not been a principle of these disciplines, including clinical psychology, for many years. Consolidation-reconsolidation-extinction models have been around for some time now, applied in particular to persons suffering from traumatic memories; e.g., Holocaust survivors, war and genocide survivors, etc.

In recent months, two teams of researchers in the UK and the US published complementary findings about the epigenetic origins of schizophrenia that have scientific communities who indulge in ‘genetic conspiracy theories’ abuzz. While these results are intriguing, and no doubt involve pathbreaking research methodologies, this line of thought represents a decontextualized understanding both of the symptoms that are typically associated with schizophrenia, and their causes.

Reuters reports that a new drug for major depression failed to improve symptoms in two late-stage clinical trials sending the manufacture’s stock into a...